DIAZEPAM (diazepam) by Medica Corp is clinical pharmacology in animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. First approved in 1990.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
Diazepam is a benzodiazepine administered via intramuscular injection that acts on the limbic system, thalamus, and hypothalamus to produce calming and anxiolytic effects. It is indicated for acute anxiety, muscle spasm, seizure management, and alcohol withdrawal, with a mechanism distinct from antipsychotics in that it lacks peripheral autonomic blocking or extrapyramidal effects. The autoinjector formulation provides equivalent bioavailability to manual syringe administration with mean Cmax of 314 ng/mL and Tmax of 1.47 hours.
As a legacy benzodiazepine approaching loss of exclusivity with 30% competitive pressure, commercial teams face declining market share and smaller resource allocation.
CLINICAL PHARMACOLOGY In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side…
Benzodiazepine
Worked on DIAZEPAM at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDiazepam offers limited career growth due to its legacy status, full genericization, and approaching loss of exclusivity. Roles focus on compliance, safety surveillance, and maintaining existing market access rather than innovation or expansion.